Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Combined ablation and radiation therapy of spinal metastases: A
novel multimodality treatment approach
Taylor J. Greenwood
Washington University School of Medicine in St. Louis

Adam Wallace
Washington University School of Medicine in St. Louis

Michael V. Friedman
Washington University School of Medicine in St. Louis

Travis J. Hillen
Washington University School of Medicine in St. Louis

Clifford G. Robinson
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Greenwood, Taylor J.; Wallace, Adam; Friedman, Michael V.; Hillen, Travis J.; Robinson, Clifford G.; and
Jennings, Jack W., ,"Combined ablation and radiation therapy of spinal metastases: A novel multimodality
treatment approach." Pain Physician. 18,6. . (2015).
https://digitalcommons.wustl.edu/open_access_pubs/8171

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Taylor J. Greenwood, Adam Wallace, Michael V. Friedman, Travis J. Hillen, Clifford G. Robinson, and Jack
W. Jennings

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/8171

Pain Physician 2015; 18:573-581 • ISSN 1533-3159

Retrospective Study

Combined Ablation and Radiation Therapy
of Spinal Metastases: A Novel Multimodality
Treatment Approach
Taylor J. Greenwood, MD1, Adam Wallace, MD1, Michael V. Friedman, MD1,
Travis J. Hillen, MD1, Clifford G. Robinson, MD2, and Jack W. Jennings, MD, PhD1

From: 1Mallinckrodt Institute
of Radiology, Washington
University in St. Louis, St.
Louis, MO; 2 Department of
Radiation Oncology, Washington
University, St. Louis, MO.
Address Correspondence:
Taylor J. Greenwood, MD
Mallinckrodt Institute of
Radiology
Washington University in Saint
Louis
510 S. Kingshighway Blvd.
St. Louis, MO 63110
E-mail:
greenwoodt@mir.wustl.edu
Disclaimer: There was no
external funding in the
preparation of this manuscript.
Conflict of interest: Dr. Jennings
is on a speaker panel and a
consultant for DFINE, INC.
Dr. Hillen is a lab instructor
with DFINE, INC. Each author
certifies that he or she, or a
member of his or her immediate
family, has no commercial
association (i.e., consultancies,
stock ownership, equity interest,
patent/licensing arrangements,
etc.) that might pose a conflict of
interest in connection with the
submitted manuscript.

Background: Radiation therapy (RT) is the current gold standard for palliation of painful
vertebral metastases. However, other percutaneous modalities such as radiofrequency ablation
(RFA), cryoablation, and vertebral augmentation have also been shown to be effective in alleviating
symptoms. Combined RT and ablation may be more effective than either therapy alone in palliating
painful metastatic disease to the spine.
Objective: To evaluate the safety and efficacy of combined ablation, either RFA or cryoablation,
and RT in the treatment of spinal metastases.
Study Design: Retrospective study.
Setting: This is a retrospective study at a single institution.
Methods: Medical records of all patients who underwent ablation of spine lesions at a single
institution between March 2012 and June 2014 were reviewed; patients treated with both RT
and either RFA or cryoablation concurrently were identified. Pain scores before and after RFA were
measured with the numerical rating scale (NRS) (0 – 10 point scale) and compared. Procedural
complications, changes in general activity level, and pain medication usage after ablation were also
recorded. When available, follow-up imaging was evaluated for evidence of residual or recurrent
disease.
Results: Twenty-one patients with 36 spine metastases were treated with RT and percutaneous
ablation concurrently; either RFA (21/22) or cryoablation (1/22). One patient received 2 separate
RFA treatments. Overall, mean worst pain score (8.0, SD = 2.3) significantly decreased at both
one week (4.3, SD = 3.1; P < .02) and 4 weeks (2.9, SD = 3.3; P < .0003). Temporary postprocedural radicular pain occurred after one RFA treatment (4.5%; 1/22). Seven patients had
radiation resistant tumors (renal cell, melanoma, or sarcoma). Post-procedural imaging (median
6 months; range 2 – 27 months) showed stable treated disease in 12/13 treatments at 3 months
and 10/10 at 6 months.
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Limitations: The therapeutic effect of vertebral augmentation versus percutaneous ablation
cannot be separated in this retrospective study. Radiation treatment protocols were variable and
included both stereotactic body and conventional RT which may have different safety and efficacy
profiles.
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Conclusion: Percutaneous ablation and concurrent RT is safe and effective in palliating painful
spinal metastases and can be effective in those who have radiation resistant tumor histology.
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ablation, cryoablation, radiation therapy, spine metastases, vertebroplasty
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T

he most common site of osseous metastases is
the spine, which accounts for 40% of all osseous
metastatic disease. Pain associated with these
metastases has a significant impact on patients’ quality
of life (1-6). Treatment of spinal metastases is usually
palliative with goals of therapy including timely control
of pain, local tumor control to prevent neurological
deficits, and mechanical stabilization to preserve
function (1). Therefore, historic treatment has been
mostly noninvasive, utilizing analgesics, chemotherapy,
and radiotherapy. Surgery is traditionally only considered
for oligometastatic or radiation resistant tumors (e.g.,
sarcoma, melanoma, and renal cell), spinal instability,
symptomatic neural compression, or intractable pain
unresponsive to non-operative measures (1).
For patients with localized pain due to spinal metastases that is uncontrolled with analgesics, systemic
chemotherapy, and/or bone-seeking radionuclides,
conventional external beam radiation therapy (cEBRT)
is the standard of care (7). However, radiation therapy
(RT) has several important clinical limitations that emphasize the need for adjunctive or alternative therapeutic modalities. First, many patients’ response to RT
is unsatisfactory with partial and complete palliation
rates of 48 – 50% and 15 – 18%, respectively (8-10).
Second, patients often develop recurrent pain, and
retreatment with RT is only effective for 40% of these
patients (9,10). Third, patients may not experience pain
relief for several weeks (9,10). Finally, once normal tissue dose limits have been reached, recurrent pain at
a previously irradiated site or adjacent vertebral level
often cannot be re-treated with additional RT.
Recent studies have demonstrated image-guided
minimally invasive techniques of radiofrequency ablation (RFA), cryoablation, and vertebral augmentation
to be safe and effective in treating symptomatic metastatic osseous disease (11-15). Percutaneous ablation
with cement stabilization not only rapidly relieves pain
(often immediately post procedure) but it does not require interruption of other systemic therapies (12-14).
Some authors have postulated that combined RT and
RFA may function synergistically to achieve better outcomes compared with RT or RFA alone (15). This study
evaluates the safety and efficacy of combined percutaneous ablation and RT in the treatment of spinal
metastases at a single institution.

Methods
This retrospective study was approved by our
institutional review board and was Health Insurance
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Portability and Accountability Act compliant. Consent
was waived for retrospective study participation. Medical records of all patients who underwent percutaneous ablation of bone lesions at our institution between
March 2012 and June 2014 were reviewed. Patients with
spinal metastases treated concurrently with either RFA
or cryoablation and conventional or stereotactic body
radiation therapy (SBRT) were identified. Concurrent
treatment was defined as less than 4 weeks between
RT and ablation. Prior to undergoing percutaneous
ablation, patients were discussed in a multidisciplinary
spinal tumor board conference including radiation
oncology, radiology, orthopedic spine surgery, and
neurosurgery.
On the day of the ablation procedure, pre-procedural worst pain in 24 hours was measured with the numerical rating scale (NRS) (0 – 10 point scale). Analgesic
use histories were also recorded by the nurse coordinator. Subsequent pain scores and changes in general activity and analgesic medication use were then obtained
via telephone interview one week and one month
after the procedure by the nurse coordinator. Analgesic medication use was defined as more, same, or less
absolute mg/day. General activity was categorized as
more, same, or less compared to pre-procedural levels.
When multiple contiguous spinal levels were treated in
a single ablation procedure, pain scores were applied to
the entire procedure as a single treatment, as it is not
typically possible to discern which individual lesion is
contributing to a patient’s pain. Chart reviews were also
performed for evidence of complications. As this was a
retrospective study, a post-ablation imaging protocol
was not established and imaging ordering was primarily directed by the treating oncologist to monitor overall disease status. When available, the post-treatment
imaging was evaluated by musculoskeletal radiologists
and neuroradiologists for evidence of residual or recurrent tumor at the treated levels.

Procedure Methods
Pre-procedural planning was performed using
cross-sectional imaging to determine pedicle access and
the expected number of targeted ablations. Magnetic
resonance imaging (MRI) was preferred due to better
evaluation of the extent of vertebral body and pedicle
involvement, as well as tumor extension into the central canal and/or neural foramen.
Prior to the procedure, written informed consent
was obtained. Conscious sedation with fentanyl and
midazolam was used in all cases, and no cases required
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general anesthesia. Local and periosteal anesthesia
was achieved with a combination of 1% lidocaine and
0.25% bupivacaine. Fluoroscopy was used for imaging
guidance for all of the RFA treatments, and computed
tomography (CT) was used for the cryoablation treatment. The vertebral bodies were accessed via a transpedicular approach using a 10-gauge introducer working
cannula. A bipedicular approach was used when the
tumor involved more than 50% of the posterior wall.
RFA was performed by using the STAR Tumor Ablation System (DFINE, San Jose, Calif), consisting of the
Spine STAR ablation instrument and the MetaSTAR generator. The number of performed ablations was determined by the tumor size and location on cross-sectional
imaging in conjunction with real-time thermocouple
temperature readings that correspond to the volume
of each individual ablation zone. The ellipsoid ablation
zone in relation to thermocouple temperatures is based
on manufacturer thermal distribution curves with maximum dimensions of 30 mm long by 20 mm wide when
the proximal thermocouple reaches 50°C and 20 mm ×
13 mm when the distal thermocouple is 50°C (16). Optimal tissue destruction occurs between 50 – 90°C (17).
The mean cumulative ablation time per lesion was 9:45
minutes (range 2:30 – 24:13 minutes). To ensure ablation of most of the tumor at the treated level, multiple
ablation zones were used with a mean of 8 overlapping
ablation zones per treated level. The tumors ranged in
size from 1.6 cm maximum diameter to involving the
entire vertebral body with paraspinal extension. The
mean temperature recorded at the proximal thermocouple on the electrode (representing the temperature
reading at the most peripheral aspect of the ablation
zone) was 50.9°C, and the mean temperature recorded
at the distal thermocouple was 74.9°C.
Cryoablation was performed with Galil (Galil Medical, Yokneam, Israel) cryoprobes. Cryoablation was performed with a 10 minute freeze cycle followed by a 7
minute active thaw and then another 10 minute freeze
cycle. CT images were obtained at both the 5 minute
and 10 minute intervals. Neuroforaminal thermal monitoring was performed in the cryoablation case. Neural
thermal protection involved neuroforaminal injection of
CO2 (18-20). This was performed by placing an 18-gauge
spinal needle in the region of the neuroforamen with
placement of a thermocouple coaxially into the neuroforamen to measure temperatures. The thermal couple
temperatures never went below 10°C (18-20).
After ablation, cement augmentation (StabiliT
Vertebral Augmentation System; DFINE, San Jose, CA)
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was performed (35/36 lesions) via the same working
cannula. The osteoblastic metastasis treated with cryoablation did not receive cement. Five (5/22) treatments
were supplemented by central epidurals or selective
nerve root blocks because of pre-existing radicular pain
or pedicle involvement by tumor.

Statistical Methods
A paired unequal variance 2-tailed Student t test
was used to compare pain scores before ablation with
pain scores one week and one month after ablation;
assuming a hypothetical mean difference of 2, P-values
< 0.05 were considered statistically significant (21,22).
Treatment responses were categorized categorically
with partial pain relief defined as ≥ 2 point pain score
reduction and complete relief defined as post-procedural pain score ≤ 1 (7,23).

Results
Twenty-one patients with 36 spine metastases
were treated with percutaneous ablation, either RFA or
cryoablation, and RT to the same level between March
2012 and June 2014. One patient received 2 separate
RFA treatments for a total of 21 RFA and one cryoablation procedures. This subgroup analysis includes 9
patients who were included in a previously reported
cohort of 73 patients (119 lesions) that had vertebral
RFA ablation (14). However, analysis of the effect of
concurrent radiation was not evaluated in that prior
study. There were 13 men (59%) and 9 women (41%).
The mean patient age was 61.8 years (range, 30 – 84
years). The most common types of primary tumor were
non-small cell lung cancer (38%, 8/21) and renal cell
carcinoma (24%, 5/21). Other tumors included breast
cancer (14%, 3/21), rectal cancer (9%, 2/21), and single
cases of bladder, angiosarcoma, and melanoma. Seven
patients had tumors that are traditionally considered
radiation resistant (renal cell, melanoma, or sarcoma).
Of the vertebral bodies treated, 42% (15/36) were thoracic and 58% (21/36) were lumbar.
The radiation therapy treatments were variable
depending on the institution and provider. The majority of patients received 30 Gy in 10 fractions (12/22).
Other treatment regimens included stereotactic body
radiation therapy (SBRT) (6/22), 20 Gy in 5 fractions
(1/22), and 8 Gy in a single fraction (1/22). Two treatment regimens were unknown.
Twenty-one RFA treatments and one cyroablation were performed in combination with RT. The
pre-procedural mean worst pain score (8.0, SD = 2.3)
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Fig. 1. Pain scale response following concurrent RT and ablation
treatment.

Table 1. Categorical response to treatment after concurrent RT and
ablation.

Pain Score Change from
Baseline

Time from RT and Ablation
1 week

1 month

Complete

5 (24%)

9 (47%)

At least partial (≥2)

16 (76%)

13 (68%)

Nonresponder (<2)

5 (24%)

6 (32%)

21

19

Total responses

significantly decreased at both one week (4.3,
SD = 3.1; P < .02) and 4 weeks (2.9, SD = 3.3;
P < .0003) following ablation treatments. The
mean worst pain decreased by 3.8 (95% CI 2.3
– 5.4) at one week and 5.1 (95% CI 3.3 – 6.9)
at 4 weeks (Fig. 1). At least partial decrease (≥
2 pain scale decrease) was reported after 76%
(16/21) and 68% (13/19) of treatments at one
week and 4 weeks, respectively. Complete pain
response (pain scale score ≤ 1) was reported
after 24% (5/21) and 47% (9/19) of treatments
at one week and one month, respectively. No
significant change in pain (< 2 pain scale difference) was reported after 24% (4/21) and 32%
(6/19) of treatments at one week and 4 weeks,
respectively (Table 1). One patient could not be
reached during the one week follow-up period.
At 4 weeks, one patient was deceased and 2
could not be reached.
Patient opioid use was decreased in 62%
(13/21), remained unchanged in 19% (4/21), and
increased in 19% (4/21) at 4 week follow-up.
General activity level at 4 weeks after ablation
treatments was increased in 81% (17/21) and
decreased in 19% (4/21) (Fig. 2). One lesion (3%;
1/36) was re-treated with RFA for recurrent pain
and imaging evidence of recurrent tumor.

Complications
According to Society of Interventional Radiology guidelines, no major complication, such

Fig. 2. Activity and pain medication use changes after concurrent RT and ablation.
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as permanent neural thermal injury, occurred as a result
of spinal percutaneous ablation. There were post procedural infections. One patient with a tumor involving the
pedicle had new radicular pain after RFA (4.5%, 1/22)
that resolved after transforaminal epidural.

Post Treatment Imaging
Thirteen (13/22) of the ablation treatments had
follow-up imaging at least 3 months later, consisting of
CT, MRI, and/or PET/CT (median 6 months; range 2 – 27
months). Five patients had between 3 and 6 months, 6
patients had between 6 – 12 months, and 2 patients had
more than 12 months of post ablation imaging. Nine of
the patients had limited or no follow-up imaging, therefore were not included in the post-procedure imaging
evaluation. Six patients had 1 – 6 weeks of follow-up
imaging and 3 patients had no imaging follow-up.
Post-procedural imaging (median 6 months; range
2 – 27 months) showed stable treated disease in 12/13
patients at 3 months and 10/10 at 6 months, despite
systemic progression of disease. Two cases (2/13) with
epidural extension had retraction of tumor from the
epidural space. There was imaging evidence of tumor
progression at the ablation margins in one patient at
3 months. Another patient with less than 3 months of
follow-up imaging had progressive vertebral collapse,
increased retropulsion, and tumor progression at 4

weeks after concurrent therapy. The remaining lesions
were stable during the duration of imaging follow-up
available (Figs. 3-6).

Discussion
Percutaneous ablation, either RFA or cyroablation,
and RT have different mechanisms of alleviating pain
and causing tumor death in spinal metastases that may
work synergistically by compensating for the other’s
shortcomings (15). Debilitating pain may be caused
by spinal cord or nerve root compression from mass
effect, pathologic fracture with mechanical instability,
periosteal nociceptor stimulation from inflammation,
tumor-derived products (e.g., tumor necrosis factor),
or tumor-induced cytokines (24,25). RFA uses thermal
energy to destroy tissue surrounding an electrode, resulting in destruction of pain sensitive nerve fibers and
decreased cytokine mediated pain from tumor necrosis
(25,26). Cryoablation relies on Joule-Thomson effect
of rapid freezing with argon gas and thawing with
helium gas as they expand to achieve cell death and
ischemia from microvascular thrombosis (27). Both RFA
and cryoablation are effective in treating osseous metastatic disease, but are dependent on the conduction of
thermal energy which dissipates with distance from the
probe tip, resulting in decreased efficacy around the
tumor edge (11-15,28). Conversely, RT is dependent on

Fig. 3. A 62-year-old man with metastatic non-small cell lung carcinoma and painful pathologic compression fracture at T8.
Sagittal T1FS post contrast image (A) one month prior to planned combined cEBRT and RFA show a pathologic fracture of T8
and diffuse enhancement of the vertebral body. Sagittal T1FS post contrast images (B, C) 1.5 months after treatment showing
tumor progression at the peripheral margins of the ablation (C) and within the posterior elements (B) (arrows). The patient’s
pre-procedural pain score (10/10) decreased to 3 at one week and 0 at 4 weeks.
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Fig. 4. A 66-year-old man with metastatic
colon cancer and painful pathologic
compression fracture of L4 that failed to
respond to cEBRT. Sagittal STIR (A)
and T1FS post contrast image (B) 2
days prior to RFA show the L4 pathologic
fracture and metastases to the adjacent L3
and L5 levels. Sagittal STIR (C) and
T1FS post contrast images (D) 2 months
after concurrent RT and RFA show
tumor progression, further L4 vertebral
body collapse and increased retropulsion
(arrows). The patient had no response to
combined therapy.

Fig. 5. A 62-year-old man with metastatic desmoplastic melanoma with right L5 radicular pain. Pretreatment axial T1FS postcontrast image at L5 (A) shows a large enhancing mass in the right aspect of L5. Stereotactic CT shows the planned radiation
isodose lines (B). SBRT and RFA (D) were performed concurrently. Post treatment axial T1FS post-contrast image at L5 (C)
demonstrates the ablation zone (arrowhead) and cement (arrow) in the right aspect of L5. Subsequent 6 month follow-up sagittal
T2 image (F) shows stable treated disease at L5 compared to pretreatment sagittal T2 image (E), while there is new multilevel
spinal disease and systemic progression (not shown) despite chemotherapy.
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oxygen for cytotoxicity and is thought to be
deficient in killing centrally located tumor
cells that are often hypoxic (29). This theory
was investigated in a retrospective cohort
study by DiStaso et al (15), who compared the
pain responses of 15 patients with solitary
axial and appendicular osseous metastases
treated with RFA followed by cEBRT (20 Gy
in 5 fractions) with 30 patients treated with
cEBRT alone. The combination therapy group
included 5 (33%; 5/15) vertebral and 2 (13%;
2/15) sacral lesions, and the RT group included 2 (6.6%; 2/30) vertebral and 8 (27%; 8/30)
sacral lesions. At 12 week follow-up, patients
in the combined treatment group more frequently reported both complete [53% (8/15)
vs 17% (5/30); P = 0.027] and at least partial
[93% (14/15) vs 60% (18/30); P = 0.048] pain
relief (15). However, only a small percentage
of their treated lesions involved the spine and
sacrum.
In this study, combined RFA and RT were
effective at alleviating pain that was uncontrollable with conventional methods. The
single case of combined RT and cryoablation
had complete response. Cryoablation is typically used in osteoblastic metastases because
the sclerotic bone lends to high impedance
and prevents efficient radiofrequency tissue
ablation. Some of the treated lesions were radiation resistant tumors based on histology or
prior radiation failure, defined as persistent
or recurrent symptoms, or imaging evidence
of tumor progression after RT. The majority
of patients were able to reduce opioid use
and increase their activity, which may lead
to an improved quality of life. In terms of
safety, one patient (4.5%; 1/22) experienced
temporary radicular pain attributable to RFA.
However, there were no permanent neurological injuries. Given these encouraging results, a randomized control trial is warranted
to compare the efficacy of combined RT and
percutaneous ablation with RT alone.
In addition to pain relief, concurrent
therapy controlled tumors locally in a majority of cases. Two patients with epidural extension of tumor had tumor retraction from
the epidural space after treatment, which
may have prevented or prolonged time to

www.painphysicianjournal.com

Fig. 6. A 62-year-old man with lumbar rectal metastases. Sagittal (A)
and axial (B) T2 images 6 weeks prior to treatment show pathologic
compression fracture at L3 and L4 with retropulsion at L4 causing
severe canal stenosis. Sagittal (C) and axial (D) T2 images 2 weeks
after completion of concurrent RT and RFA show tumor retraction from
the canal at L4. Two months after treatment, CT (not shown) revealed
mild osseous canal stenosis without soft tissue in the epidural space.

malignant spinal cord compression. These results are particularly
intriguing given recent technical advances that permit ablation
of metastases involving the posterior vertebral body and pedicles
with navigational radiofrequency probes that permit real-time
monitoring of the ablation volume (14,16,30). Additionally, the
risk of radiation myelopathy often precludes adequate treatment of tumor involving the posterior vertebral body, pedicles,
neural foramina, and/or epidural space. Both ablation and SBRT
of radiation resistant tumors alone have a higher likelihood of
failure when the tumor involves the pedicles and neuroforamen
(14,31). Randomized control trials are needed to assess whether
combined therapy achieves superior local tumor control compared with RT alone.
There are several limitations of this retrospective study. The
efficacy of combined RFA and RT for pain palliation cannot be
isolated from that of vertebral augmentation, which was per-
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formed after all RFA cases to stabilize or prevent pathologic fracture. Pain relief from cementoplasty alone in
treatment of metastatic compression fractures has been
shown to be effective over non-surgical management
(32,33). Cementoplasty is considered to produce pain
relief via internal trabecular stabilization resulting in
the reduced activity of periosteal nerves. The exothermic reaction resulting from polymethyl methacrylate
production destroys adjacent pain fibers. Percutaneous
ablation may have a synergistic pain relieving response
with cementoplasty. Additionally, RFA has the theoretical advantage of preventing displacement of viable
tumors into the venous plexus though venous plexus
thrombosis and tumor cell death (34-37).
The prescribed RT regimens in this study were
variable including both conventional single and fractionated RT, as well as SBRT, which may have different
safety and efficacy profiles. There is ongoing debate
regarding which RT regimen to employ (5). However,
data are accumulating in support of SBRT for spinal metastases in oligometastatic disease and radioresistant

histology. Future prospective, multi-armed trials should
randomize patients with pathologic stable fractures to
RT and vertebral augmentation; RT, ablation, and vertebral augmentation; and ablation plus augmentation
in order to elucidate the most effective multimodality
oftreatment in the palliative management of metastatic spine disease.

Conclusion
Combined radiation therapy and percutaneous
ablation is safe and effective in palliating painful spinal
metastases and controlling local tumor progression.
This combined therapy is also effective in traditionally resistant tumor histology. Future prospective multiarmed studies should be designed to determine the
palliative and local tumor control benefit of combined
RT and percutaneous ablation, particularly for radiation resistant tumors and metastases involving the posterior vertebral body, pedicles, neural foramina, and/or
epidural space that cannot be adequately treated with
either modality alone.
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